Literature DB >> 9436190

Neuroblastoma: biology and therapy.

K K Matthay1.   

Abstract

Neuroblastoma is the most common extracranial solid tumor of childhood, accounting for 15% of cancer-related deaths. These tumors have a predilection for young children; 60% of cases occur before age 2 years and 97% before age 10. Neuroblastomas derive from embryonic neural crest cells of the peripheral sympathetic nervous system. The behavior of this malignancy is characterized by marked clinical heterogeneity, ranging from spontaneous maturation in some patients to inexorable rapid metastatic progression in others. This article will discuss some of the molecular and biological features of neuroblastoma that are associated with these differences in behavior, and how these features have been used to develop a risk-based approach to therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9436190

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  16 in total

1.  Characteristics of stem cells from human neuroblastoma cell lines and in tumors.

Authors:  Jeanette D Walton; David R Kattan; Sharon K Thomas; Barbara A Spengler; Hong-Fen Guo; June L Biedler; Nai-Kong V Cheung; Robert A Ross
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

2.  Comparison of effective radiation doses from X-ray, CT, and PET/CT in pediatric patients with neuroblastoma using a dose monitoring program.

Authors:  Yeun Yoon Kim; Hyun Joo Shin; Myung Joon Kim; Mi-Jung Lee
Journal:  Diagn Interv Radiol       Date:  2016 Jul-Aug       Impact factor: 2.630

3.  TRAIL activates a caspase 9/7-dependent pathway in caspase 8/10-defective SK-N-SH neuroblastoma cells with two functional end points: induction of apoptosis and PGE2 release.

Authors:  Giorgio Zauli; Daniela Milani; Erika Rimondi; Giovanna Baldini; Vanessa Nicolin; Vittorio Grill; Paola Secchiero
Journal:  Neoplasia       Date:  2003 Sep-Oct       Impact factor: 5.715

4.  The effect of carvacrol on healthy neurons and N2a cancer cells: some biochemical, anticancerogenicity and genotoxicity studies.

Authors:  Elanur Aydın; Hasan Türkez; M Sait Keleş
Journal:  Cytotechnology       Date:  2013-04-04       Impact factor: 2.058

Review 5.  Neuroblastoma: evolving therapies for a disease with many faces.

Authors:  Robert E Goldsby; Katherine K Matthay
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

6.  Circ_0132817 facilitates cell proliferation, migration, invasion and glycolysis by regulating the miR-432-5p/NOL4L axis in neuroblastoma.

Authors:  Yafei Fang; Yuqian Yao; Kangwei Mao; Yanyan Zhong; Yan Xu
Journal:  Exp Brain Res       Date:  2021-04-10       Impact factor: 1.972

7.  Treatment results and prognostic factors of pediatric neuroblastoma: a retrospective study.

Authors:  Mohamed I El-Sayed; Amany M Ali; Heba A Sayed; Eman M Zaky
Journal:  Int Arch Med       Date:  2010-12-24

8.  A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity.

Authors:  Nidia Alvarez-Rueda; Ariane Desselle; Denis Cochonneau; Tanguy Chaumette; Béatrice Clemenceau; Stéphanie Leprieur; Gwenola Bougras; Stéphane Supiot; Jean-Marie Mussini; Jacques Barbet; Julie Saba; François Paris; Jacques Aubry; Stéphane Birklé
Journal:  PLoS One       Date:  2011-09-22       Impact factor: 3.240

9.  Decreased aortic growth and middle aortic syndrome in patients with neuroblastoma after radiation therapy.

Authors:  Elizabeth J Sutton; Ricky T Tong; Amy M Gillis; Tobias D Henning; Vivian A Weinberg; Sophie Boddington; Daphne A Haas-Kogan; Katherine Matthay; Vinil Sha; Charles Gooding; Fergus V Coakley; Heike Daldrup-Link
Journal:  Pediatr Radiol       Date:  2009-09-18

10.  Long Noncoding RNA LINC01410 Suppresses Tumorigenesis and Enhances Radiosensitivity in Neuroblastoma Cells Through Regulating miR-545-3p/HK2 Axis.

Authors:  Liping Mou; Lili Wang; Shaoming Zhang; Qinghua Wang
Journal:  Onco Targets Ther       Date:  2021-05-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.